TP53 is altered in 14.93% of acute myeloid leukemia patients with TP53 Mutation present in 13.19% of all acute myeloid leukemia patients [4].

TP53 Mutation is an inclusion criterion in 112 clinical trials for acute myeloid leukemia, of which 71 are open and 41 are closed. Of the trials that contain TP53 Mutation and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 34 are phase 1 (19 open), 19 are phase 1/phase 2 (13 open), 46 are phase 2 (31 open), 2 are phase 2/phase 3 (1 open), 8 are phase 3 (6 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 18.0% of myelodysplastic syndromes patients with TP53 Mutation present in 16.3% of all myelodysplastic syndromes patients [4].

TP53 Mutation is an inclusion criterion in 72 clinical trials for myelodysplastic syndromes, of which 47 are open and 25 are closed. Of the trials that contain TP53 Mutation and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 25 are phase 1 (14 open), 13 are phase 1/phase 2 (11 open), 28 are phase 2 (19 open), 1 is phase 2/phase 3 (0 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [5].

TP53 Mutation is an inclusion criterion in 40 clinical trials for acute lymphoblastic leukemia, of which 24 are open and 16 are closed. Of the trials that contain TP53 Mutation and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 15 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), 18 are phase 2 (11 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 1.69% of chronic myeloid leukemia patients with TP53 Mutation present in 1.69% of all chronic myeloid leukemia patients [4].

TP53 Mutation is an inclusion criterion in 27 clinical trials for chronic myeloid leukemia, of which 16 are open and 11 are closed. Of the trials that contain TP53 Mutation and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 11 are phase 1 (7 open), 4 are phase 1/phase 2 (4 open), 10 are phase 2 (5 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 13.85% of hodgkin lymphoma patients with TP53 Mutation present in 13.85% of all hodgkin lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 20 clinical trials for hodgkin lymphoma, of which 11 are open and 9 are closed. Of the trials that contain TP53 Mutation and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 4.57% of chronic myelomonocytic leukemia patients with TP53 Mutation present in 4.06% of all chronic myelomonocytic leukemia patients [4].

TP53 Mutation is an inclusion criterion in 19 clinical trials for chronic myelomonocytic leukemia, of which 15 are open and 4 are closed. Of the trials that contain TP53 Mutation and chronic myelomonocytic leukemia as inclusion criteria, 6 are phase 1 (3 open), 6 are phase 1/phase 2 (6 open), and 7 are phase 2 (6 open) [5].

TP53 is altered in 17.79% of non-hodgkin lymphoma patients with TP53 Mutation present in 15.07% of all non-hodgkin lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain TP53 Mutation and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (5 open) [5].

TP53 is altered in 8.91% of multiple myeloma patients with TP53 Mutation present in 8.1% of all multiple myeloma patients [4].

TP53 Mutation is an inclusion criterion in 17 clinical trials for multiple myeloma, of which 12 are open and 5 are closed. Of the trials that contain TP53 Mutation and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (6 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is no phase specified (0 open) [5].

TP53 Mutation is an inclusion criterion in 17 clinical trials for chronic lymphocytic leukemia, of which 12 are open and 5 are closed. Of the trials that contain TP53 Mutation and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (8 open), and 1 is phase 3 (0 open) [5].

TP53 Mutation is an inclusion criterion in 13 clinical trials for acute biphenotypic leukemia, of which 6 are open and 7 are closed. Of the trials that contain TP53 Mutation and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 28.89% of mantle cell lymphoma patients with TP53 Mutation present in 25.56% of all mantle cell lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 11 clinical trials for mantle cell lymphoma, of which 6 are open and 5 are closed. Of the trials that contain TP53 Mutation and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 4 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 43.65% of malignant solid tumor patients with TP53 Mutation present in 35.96% of all malignant solid tumor patients [4].

TP53 Mutation is an inclusion criterion in 10 clinical trials for malignant solid tumor, of which 6 are open and 4 are closed. Of the trials that contain TP53 Mutation and malignant solid tumor as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [5].

TP53 is altered in 15.99% of lymphoma patients with TP53 Mutation present in 13.65% of all lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 9 clinical trials for lymphoma, of which 5 are open and 4 are closed. Of the trials that contain TP53 Mutation and lymphoma as inclusion criteria, 6 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

TP53 is altered in 43.75% of Burkitt lymphoma patients with TP53 Mutation present in 43.75% of all Burkitt lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 8 clinical trials for Burkitt lymphoma, of which 3 are open and 5 are closed. Of the trials that contain TP53 Mutation and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 49.94% of non-small cell lung carcinoma patients with TP53 Mutation present in 41.79% of all non-small cell lung carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 4 are open and 4 are closed. Of the trials that contain TP53 Mutation and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (2 open) [5].

TP53 is altered in 16.24% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 Mutation present in 14.55% of all chronic lymphocytic leukemia/small lymphocytic lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 7 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 4 are open and 3 are closed. Of the trials that contain TP53 Mutation and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 14.85% of acute leukemia patients with TP53 Mutation present in 13.16% of all acute leukemia patients [4].

TP53 Mutation is an inclusion criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain TP53 Mutation and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 13.16% of anaplastic large cell lymphoma patients with TP53 Mutation present in 5.26% of all anaplastic large cell lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 7 clinical trials for anaplastic large cell lymphoma, of which 3 are open and 4 are closed. Of the trials that contain TP53 Mutation and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 5.07% of myelodysplastic/myeloproliferative neoplasm patients with TP53 Mutation present in 4.39% of all myelodysplastic/myeloproliferative neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 7 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 6 are open and 1 is closed. Of the trials that contain TP53 Mutation and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (2 open) [5].

TP53 is altered in 3.96% of myeloproliferative neoplasm patients with TP53 Mutation present in 3.56% of all myeloproliferative neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 7 clinical trials for myeloproliferative neoplasm, of which 4 are open and 3 are closed. Of the trials that contain TP53 Mutation and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [5].

TP53 Mutation is an inclusion criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain TP53 Mutation and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [5].

TP53 is altered in 74.28% of ovarian carcinoma patients with TP53 Mutation present in 58.14% of all ovarian carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 6 clinical trials for ovarian carcinoma, of which 2 are open and 4 are closed. Of the trials that contain TP53 Mutation and ovarian carcinoma as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [5].

TP53 is altered in 10.12% of follicular lymphoma patients with TP53 Mutation present in 8.9% of all follicular lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 6 clinical trials for follicular lymphoma, of which 2 are open and 4 are closed. Of the trials that contain TP53 Mutation and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 4.22% of myelofibrosis patients with TP53 Mutation present in 3.61% of all myelofibrosis patients [4].

TP53 Mutation is an inclusion criterion in 6 clinical trials for myelofibrosis, of which 2 are open and 4 are closed. Of the trials that contain TP53 Mutation and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 2 are phase 2 (1 open) [5].

TP53 is altered in 4.88% of marginal zone lymphoma patients with TP53 Mutation present in 2.44% of all marginal zone lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain TP53 Mutation and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [5].

TP53 Mutation is an inclusion criterion in 6 clinical trials for small lymphocytic lymphoma, of which 3 are open and 3 are closed. Of the trials that contain TP53 Mutation and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

TP53 is altered in 36.14% of secondary acute myeloid leukemia patients with TP53 Mutation present in 34.94% of all secondary acute myeloid leukemia patients [4].

TP53 Mutation is an inclusion criterion in 5 clinical trials for secondary acute myeloid leukemia, of which 5 are open and 0 are closed. Of the trials that contain TP53 Mutation and secondary acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (2 open) [5].

TP53 is altered in 39.68% of breast carcinoma patients with TP53 Mutation present in 29.89% of all breast carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 1 is open and 4 are closed. Of the trials that contain TP53 Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 2 are phase 2 (0 open) [5].

TP53 is altered in 25.0% of prolymphocytic leukemia patients with TP53 Mutation present in 25.0% of all prolymphocytic leukemia patients [4].

TP53 Mutation is an inclusion criterion in 5 clinical trials for prolymphocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain TP53 Mutation and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [5].

TP53 is altered in 24.15% of diffuse large B-cell lymphoma patients with TP53 Mutation present in 20.57% of all diffuse large B-cell lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 5 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 1 is closed. Of the trials that contain TP53 Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), and 1 is phase 2 (1 open) [5].

TP53 is altered in 18.6% of refractory anemia with excess blasts patients with TP53 Mutation present in 18.14% of all refractory anemia with excess blasts patients [4].

TP53 Mutation is an inclusion criterion in 5 clinical trials for refractory anemia with excess blasts, of which 3 are open and 2 are closed. Of the trials that contain TP53 Mutation and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [5].

TP53 is altered in 28.78% of prostate carcinoma patients with TP53 Mutation present in 21.03% of all prostate carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 4 clinical trials for prostate carcinoma, of which 3 are open and 1 is closed. Of the trials that contain TP53 Mutation and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [5].

TP53 Mutation is an inclusion criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain TP53 Mutation and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].

TP53 Mutation is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain TP53 Mutation and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [5].

TP53 is altered in 88.0% of endometrial serous adenocarcinoma patients with TP53 Mutation present in 78.91% of all endometrial serous adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for endometrial serous adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain TP53 Mutation and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [5].

TP53 is altered in 87.3% of fallopian tube carcinoma patients with TP53 Mutation present in 66.67% of all fallopian tube carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for fallopian tube carcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 Mutation and fallopian tube carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

TP53 is altered in 70.7% of adenocarcinoma of the gastroesophageal junction patients with TP53 Mutation present in 63.71% of all adenocarcinoma of the gastroesophageal junction patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 1 is closed. Of the trials that contain TP53 Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [5].

TP53 is altered in 78.26% of primary peritoneal carcinoma patients with TP53 Mutation present in 43.48% of all primary peritoneal carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 Mutation and primary peritoneal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

TP53 is altered in 47.46% of bladder carcinoma patients with TP53 Mutation present in 42.09% of all bladder carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 1 is open and 2 are closed. Of the trials that contain TP53 Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

TP53 is altered in 36.14% of therapy-related acute myeloid leukemia patients with TP53 Mutation present in 34.94% of all therapy-related acute myeloid leukemia patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain TP53 Mutation and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

TP53 is altered in 42.25% of therapy-related myelodysplastic syndrome patients with TP53 Mutation present in 33.8% of all therapy-related myelodysplastic syndrome patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain TP53 Mutation and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

TP53 is altered in 36.79% of glioblastoma patients with TP53 Mutation present in 33.57% of all glioblastoma patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for glioblastoma, of which 0 are open and 3 are closed. Of the trials that contain TP53 Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [5].

TP53 is altered in 17.6% of myelodysplastic syndrome with excess blasts-2 patients with TP53 Mutation present in 17.6% of all myelodysplastic syndrome with excess blasts-2 patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain TP53 Mutation and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [5].

TP53 is altered in 19.49% of B-cell non-hodgkin lymphoma patients with TP53 Mutation present in 16.84% of all B-cell non-hodgkin lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

TP53 is altered in 12.5% of mixed phenotype acute leukemia patients with TP53 Mutation present in 12.5% of all mixed phenotype acute leukemia patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 1 is closed. Of the trials that contain TP53 Mutation and mixed phenotype acute leukemia as inclusion criteria, 3 are phase 2 (2 open) [5].

TP53 is altered in 11.11% of lymphoplasmacytic lymphoma patients with TP53 Mutation present in 11.11% of all lymphoplasmacytic lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain TP53 Mutation and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [5].

TP53 is altered in 4.05% of T-cell lymphoblastic leukemia/lymphoma patients with TP53 Mutation present in 4.05% of all T-cell lymphoblastic leukemia/lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 Mutation and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [5].

TP53 Mutation is an inclusion criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 Mutation and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

TP53 Mutation is an inclusion criterion in 3 clinical trials for plasma cell leukemia, of which 1 is open and 2 are closed. Of the trials that contain TP53 Mutation and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [5].

TP53 Mutation is an inclusion criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain TP53 Mutation and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

TP53 is altered in 89.66% of high grade ovarian serous adenocarcinoma patients with TP53 Mutation present in 68.72% of all high grade ovarian serous adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TP53 is altered in 87.3% of high grade fallopian tube serous adenocarcinoma patients with TP53 Mutation present in 66.67% of all high grade fallopian tube serous adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TP53 is altered in 82.84% of small cell lung carcinoma patients with TP53 Mutation present in 64.74% of all small cell lung carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 0 are open and 2 are closed. Of the trials that contain TP53 Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

TP53 is altered in 75.72% of squamous cell lung carcinoma patients with TP53 Mutation present in 62.45% of all squamous cell lung carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 Mutation and squamous cell lung carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

TP53 is altered in 66.31% of anaplastic astrocytoma patients with TP53 Mutation present in 60.48% of all anaplastic astrocytoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 0 are open and 2 are closed. Of the trials that contain TP53 Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

TP53 is altered in 68.53% of colorectal adenocarcinoma patients with TP53 Mutation present in 59.12% of all colorectal adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for colorectal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 Mutation and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

TP53 is altered in 68.42% of colorectal carcinoma patients with TP53 Mutation present in 59.03% of all colorectal carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 0 are open and 2 are closed. Of the trials that contain TP53 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

TP53 is altered in 78.26% of primary peritoneal serous adenocarcinoma patients with TP53 Mutation present in 43.48% of all primary peritoneal serous adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for primary peritoneal serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TP53 is altered in 48.34% of head and neck squamous cell carcinoma patients with TP53 Mutation present in 40.68% of all head and neck squamous cell carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

TP53 is altered in 45.06% of urothelial carcinoma patients with TP53 Mutation present in 39.96% of all urothelial carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TP53 is altered in 20.0% of acute undifferentiated leukemia patients with TP53 Mutation present in 20.0% of all acute undifferentiated leukemia patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for acute undifferentiated leukemia, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TP53 is altered in 13.38% of leukemia patients with TP53 Mutation present in 11.88% of all leukemia patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for leukemia, of which 1 is open and 1 is closed. Of the trials that contain TP53 Mutation and leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

TP53 is altered in 12.27% of mature T-cell and NK-cell neoplasm patients with TP53 Mutation present in 9.49% of all mature T-cell and NK-cell neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain TP53 Mutation and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

TP53 Mutation is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

TP53 Mutation is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [5].

TP53 Mutation is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain TP53 Mutation and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [5].

TP53 Mutation is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 Mutation and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [5].

TP53 Mutation is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 Mutation and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [5].

TP53 Mutation is an inclusion criterion in 2 clinical trials for refractory anemia, of which 1 is open and 1 is closed. Of the trials that contain TP53 Mutation and refractory anemia as inclusion criteria, 2 are phase 2 (1 open) [5].

TP53 is altered in 87.33% of esophageal squamous cell carcinoma patients with TP53 Mutation present in 68.67% of all esophageal squamous cell carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 81.87% of uterine carcinosarcoma patients with TP53 Mutation present in 68.28% of all uterine carcinosarcoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for uterine carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and uterine carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 81.26% of esophageal carcinoma patients with TP53 Mutation present in 68.24% of all esophageal carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 66.67% of anaplastic oligoastrocytoma patients with TP53 Mutation present in 64.58% of all anaplastic oligoastrocytoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

TP53 is altered in 77.08% of ovarian serous tumor patients with TP53 Mutation present in 60.16% of all ovarian serous tumor patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for ovarian serous tumor, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and ovarian serous tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 67.86% of malignant intestinal neoplasm patients with TP53 Mutation present in 58.47% of all malignant intestinal neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 68.57% of malignant esophagogastric neoplasm patients with TP53 Mutation present in 57.96% of all malignant esophagogastric neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 68.91% of pancreatic carcinoma patients with TP53 Mutation present in 56.33% of all pancreatic carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 68.68% of pancreatic adenocarcinoma patients with TP53 Mutation present in 56.05% of all pancreatic adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 52.94% of gliosarcoma patients with TP53 Mutation present in 51.47% of all gliosarcoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and gliosarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

TP53 is altered in 53.44% of ampulla of vater carcinoma patients with TP53 Mutation present in 45.5% of all ampulla of vater carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 53.94% of gastric carcinoma patients with TP53 Mutation present in 44.46% of all gastric carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TP53 is altered in 53.94% of malignant gastric neoplasm patients with TP53 Mutation present in 44.46% of all malignant gastric neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 53.66% of gastric adenocarcinoma patients with TP53 Mutation present in 44.3% of all gastric adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 47.94% of WHO grade III glioma patients with TP53 Mutation present in 43.81% of all WHO grade III glioma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and WHO grade III glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

TP53 is altered in 49.47% of malignant small intestinal neoplasm patients with TP53 Mutation present in 40.35% of all malignant small intestinal neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 45.24% of lung adenocarcinoma patients with TP53 Mutation present in 38.06% of all lung adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 40.3% of endometrial carcinoma patients with TP53 Mutation present in 35.63% of all endometrial carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

TP53 is altered in 42.25% of secondary myelodysplastic syndrome patients with TP53 Mutation present in 33.8% of all secondary myelodysplastic syndrome patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 40.93% of cancer patients with TP53 Mutation present in 33.78% of all cancer patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 37.19% of head and neck carcinoma patients with TP53 Mutation present in 30.45% of all head and neck carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 28.57% of adult T-cell leukemia/lymphoma patients with TP53 Mutation present in 28.57% of all adult T-cell leukemia/lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [5].

TP53 is altered in 42.86% of breast lobular carcinoma in situ patients with TP53 Mutation present in 28.57% of all breast lobular carcinoma in situ patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

TP53 is altered in 25.0% of acute megakaryoblastic leukemia patients with TP53 Mutation present in 25.0% of all acute megakaryoblastic leukemia patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 25.0% of T-cell prolymphocytic leukemia patients with TP53 Mutation present in 25.0% of all T-cell prolymphocytic leukemia patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 27.67% of acute myeloid leukemia with myelodysplasia-related changes patients with TP53 Mutation present in 24.0% of all acute myeloid leukemia with myelodysplasia-related changes patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [5].

TP53 is altered in 26.66% of cholangiocarcinoma patients with TP53 Mutation present in 21.23% of all cholangiocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 28.47% of prostate adenocarcinoma patients with TP53 Mutation present in 20.84% of all prostate adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 19.5% of melanoma patients with TP53 Mutation present in 16.86% of all melanoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 16.67% of mediastinal large B-cell lymphoma patients with TP53 Mutation present in 16.67% of all mediastinal large B-cell lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 22.92% of ovarian endometrioid adenocarcinoma patients with TP53 Mutation present in 15.97% of all ovarian endometrioid adenocarcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 23.58% of sarcoma patients with TP53 Mutation present in 15.35% of all sarcoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 13.33% of acute leukemia of ambiguous lineage patients with TP53 Mutation present in 13.33% of all acute leukemia of ambiguous lineage patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 13.57% of malignant testicular neoplasm patients with TP53 Mutation present in 11.81% of all malignant testicular neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for malignant testicular neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and malignant testicular neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 13.33% of Ewing sarcoma patients with TP53 Mutation present in 11.79% of all Ewing sarcoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 12.87% of myeloid neoplasm patients with TP53 Mutation present in 11.5% of all myeloid neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 15.2% of rhabdomyosarcoma patients with TP53 Mutation present in 11.27% of all rhabdomyosarcoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 12.43% of mature T-cell and NK-cell non-hodgkin lymphoma patients with TP53 Mutation present in 9.25% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 12.43% of T-cell non-hodgkin lymphoma patients with TP53 Mutation present in 9.25% of all T-cell non-hodgkin lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 12.12% of myelodysplastic/myeloproliferative neoplasm, unclassifiable patients with TP53 Mutation present in 9.09% of all myelodysplastic/myeloproliferative neoplasm, unclassifiable patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 11.67% of kidney carcinoma patients with TP53 Mutation present in 8.91% of all kidney carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and kidney carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 8.87% of plasma cell neoplasm patients with TP53 Mutation present in 8.06% of all plasma cell neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 9.95% of clear cell renal cell carcinoma patients with TP53 Mutation present in 7.93% of all clear cell renal cell carcinoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 7.14% of chronic myelomonocytic leukemia-2 patients with TP53 Mutation present in 7.14% of all chronic myelomonocytic leukemia-2 patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TP53 is altered in 9.0% of indolent non-hodgkin lymphoma patients with TP53 Mutation present in 7.11% of all indolent non-hodgkin lymphoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 5.41% of chronic myelomonocytic leukemia-1 patients with TP53 Mutation present in 5.41% of all chronic myelomonocytic leukemia-1 patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-1, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TP53 is altered in 5.17% of gastrointestinal stromal tumor patients with TP53 Mutation present in 4.53% of all gastrointestinal stromal tumor patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 is altered in 4.0% of chronic myelomonocytic leukemia-0 patients with TP53 Mutation present in 4.0% of all chronic myelomonocytic leukemia-0 patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-0, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and chronic myelomonocytic leukemia-0 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TP53 is altered in 4.42% of primary myelofibrosis patients with TP53 Mutation present in 3.98% of all primary myelofibrosis patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TP53 is altered in 4.0% of polycythemia vera patients with TP53 Mutation present in 2.86% of all polycythemia vera patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 is altered in 2.41% of neuroblastoma patients with TP53 Mutation present in 1.6% of all neuroblastoma patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 2.53% of desmoplastic small round cell tumor patients with TP53 Mutation present in 1.27% of all desmoplastic small round cell tumor patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 is altered in 1.09% of histiocytic and dendritic cell neoplasm patients with TP53 Mutation present in 0.73% of all histiocytic and dendritic cell neoplasm patients [4].

TP53 Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for acute promyelocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and acute promyelocytic leukemia as inclusion criteria, 1 is no phase specified (0 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for hereditary breast and ovarian cancer syndrome, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 Mutation and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [5].